Brief: Heron Therapeutics Announces Settlement With Mylan Related To Cinvanti® And Aponvie® Patent Litigations
06/05/2025 12:31
May 6 (Reuters) - Heron Therapeutics Inc HRTX.O: HERON THERAPEUTICS ANNOUNCES SETTLEMENT WITH MYLAN RELATED TO CINVANTI® AND APONVIE® PATENT LITIGATIONS HERON THERAPEUTICS: GRANTS MYLAN LICENSE TO MARKET GENERIC CINVANTI AND APONVIE BEGINNING JUNE 2032 Source text: ID:nPn2JZnjGa Further company coverage: HRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop